Am I a Candidate for GLP-1 Medication for Weight Loss?

GLP-1 medications are injectable prescription drugs (semaglutide, tirzepatide, liraglutide) that mimic the GLP-1 hormone to reduce appetite, slow gastric emptying, and improve blood-sugar control. The FDA approves them for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as hypertension, high cholesterol, prediabetes, or type 2 diabetes.

You are likely a candidate for GLP-1 weight-loss medication if you are an adult with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as prediabetes, type 2 diabetes, high blood pressure, or high cholesterol. A licensed clinician still needs to confirm this based on your full medical history. Start your GLP-1 evaluation at Teledris to get a personalized answer in about 24 hours.

Who usually qualifies for GLP-1 weight-loss treatment?

The people most likely to qualify are US adults aged 18 and older who have tried diet and exercise and still carry excess weight that affects their health. The FDA prescribing information for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide) defines eligibility by BMI and by the presence of weight-related conditions. These same thresholds are used by most telehealth clinics, including Teledris, because they are the standard of care under American Association of Clinical Endocrinology (AACE) and American Diabetes Association (ADA) guidance.

You do not need to have diabetes to qualify. In the STEP-1 trial published in the New England Journal of Medicine in 2021, Wilding and colleagues showed semaglutide produced a 14.9% average body-weight loss at 68 weeks in adults with obesity but without diabetes. That evidence is why the FDA approved semaglutide for chronic weight management in non-diabetic adults who meet the BMI criteria below.

Teledris supports English and Spanish throughout — from the intake form to clinician messaging. In our comparison of semaglutide vs tirzepatide we cover efficacy side-by-side, so you can learn which molecule likely fits your goal before you start. For now, the first question is whether you meet the basic clinical criteria.

What BMI do you need for GLP-1 medication?

You need a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related medical condition. Per the FDA prescribing information for Wegovy (semaglutide 2.4 mg) and Zepbound (tirzepatide), those are the exact thresholds for chronic weight management in adults. To calculate your BMI, divide your weight in kilograms by your height in meters squared — or use an online calculator and enter your height and weight in pounds and inches.

BMI 30 and above

A BMI of 30 or higher is classified as obesity. If your BMI is in this range, you meet the primary FDA eligibility criterion for both Wegovy and Zepbound without needing an additional diagnosis. This is the most common entry point for GLP-1 care at Teledris — about two in three approved patients meet it this way. A clinician will still review your history to rule out contraindications, which we cover below.

BMI 27 with a weight-related condition

If your BMI is between 27 and 29.9, you can still qualify, but you must also have at least one documented weight-related comorbidity. The FDA specifically lists conditions such as hypertension, type 2 diabetes, and dyslipidemia. Prediabetes, obstructive sleep apnea, cardiovascular disease, and fatty liver disease are also widely accepted under AACE/ADA obesity guidance. You do not need an in-person visit to document these — recent lab work or a prior diagnosis in your medical history is usually enough.

Why BMI is only the starting point

BMI is a screening tool, not a diagnosis. It can underestimate risk in people with high muscle mass and overestimate it in others. That is why Teledris clinicians also review waist circumference, A1c, lipid panel, blood pressure, and weight history before deciding. If your BMI is on the border (say, 26.8) but you have prediabetes and a family history of type 2 diabetes, a clinician can still make a clinical case for treatment after reviewing your full picture.

What health conditions can make you eligible sooner?

Several common conditions lower the qualifying BMI threshold because they raise metabolic risk and make weight loss medically necessary. If you have any of these, a BMI of 27 — not 30 — may be enough to qualify under FDA rules and AACE/ADA clinical guidance.

Prediabetes is one of the most common. It is defined by a hemoglobin A1c between 5.7% and 6.4% or a fasting glucose between 100 and 125 mg/dL. The ADA Standards of Care recommend weight loss of 5-10% to reduce the risk of progressing to type 2 diabetes, and GLP-1 medications reliably exceed that threshold. Type 2 diabetes itself also qualifies you, and in that case semaglutide or tirzepatide can be prescribed for both glucose control and weight loss.

Hypertension is another qualifying condition. The American Heart Association defines it as a blood pressure of 130/80 mm Hg or higher. Dyslipidemia — elevated LDL cholesterol, low HDL, or high triglycerides — also counts. Obstructive sleep apnea, now formally listed on the Zepbound label after the 2024 FDA expansion, and non-alcoholic fatty liver disease (MASLD) are recognized weight-related conditions as well.

Polycystic ovary syndrome (PCOS) deserves a special mention. GLP-1 medications are not FDA-approved specifically for PCOS, but many PCOS patients meet the obesity-component criteria (BMI 27+ with insulin resistance) and are prescribed GLP-1s off-label under clinician supervision. Cardiovascular disease and a prior heart attack or stroke are also well-recognized indications under the 2023 FDA-approved cardiovascular benefit label for Wegovy.

Who should not start GLP-1 without medical review?

Some people should not take GLP-1 medication at all, and others need extra review before starting. The clearest absolute contraindication is a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Both Wegovy and Zepbound carry an FDA black box warning about this — the risk is based on rodent studies and has not been proven in humans, but the contraindication is firm on the label.

Pregnancy is another hard stop. GLP-1 medications are not approved during pregnancy, and women who are actively trying to conceive should stop at least two months before (semaglutide) or four weeks before (tirzepatide) because of the long half-life. Breastfeeding is also a caution requiring clinician judgment. A history of pancreatitis, severe gastroparesis (delayed stomach emptying), or current gallbladder disease are other reasons to pause and have a detailed clinician review before starting.

Type 1 diabetes is an off-label situation — GLP-1 medications are only FDA-approved in type 2 diabetes, but a specialist may still prescribe in type 1 for the weight and glucose-variability benefit, with close monitoring. An active eating disorder, especially bulimia or anorexia nervosa, is generally a reason not to prescribe GLP-1s because the appetite-suppression mechanism can worsen restrictive patterns. Finally, if you are under 18, note that tirzepatide is not approved for pediatric use and semaglutide is only approved down to age 12 for obesity under a specific label.

How to tell if you are ready for a GLP-1 evaluation

Clinical eligibility is only half the picture — personal readiness is the other half. GLP-1 treatment works best when you commit to a weekly subcutaneous injection, steady hydration, and real changes to how you eat. Most patients inject on the same day each week using a prefilled pen in the thigh, abdomen, or upper arm — it takes about ten seconds and the needle is short and thin.

You should also be ready to eat differently for a while. Smaller portions, more protein (about 1.0 to 1.6 grams per kilogram of body weight — roughly 0.5 to 0.7 grams per pound), and consistent water intake reduce nausea and protect muscle mass during rapid weight loss. The first 8-12 weeks are the adjustment window — most of the early nausea, constipation, and fatigue resolve once your body adapts to the medication. For the full protein, fiber, and hydration targets, our weight-loss nutrition guide breaks down the plate structure that makes GLP-1 treatment work.

Finally, think in months, not weeks. Peer-reviewed trials show weight loss continues past week 52 on both semaglutide and tirzepatide. A commitment of at least 12 months gives you the best chance of meaningful, durable weight loss. If you are not ready, that is useful information too — a Teledris clinician can help you decide whether now or later is the right time.

What happens after you start the Teledris evaluation?

The Teledris GLP-1 evaluation takes about two minutes to complete. You enter your height, weight, medical history, current medications, and goals, and upload any recent lab work if you have it. The form is available in English and Spanish and adapts questions to your answers so you only see what is relevant.

A licensed US clinician reviews your profile — usually within 24 hours — and responds with one of three decisions. If approved, you receive a prescription for Wegovy, Ozempic, Zepbound, or Mounjaro (depending on your profile), and the medication ships discreetly to your door in cold-chain packaging. If the clinician needs more information, they message you to request labs or clarify a detail. If GLP-1 is not appropriate, they explain why in plain language and suggest alternatives.

Once you start, ongoing care is included. You can message your clinician about side effects, dose titration, plateaus, or lifestyle questions any time — most replies come within a business day. Our comparison of semaglutide vs tirzepatide covers efficacy side-by-side if you are curious which molecule you will likely be prescribed, and our realistic 30/60/90 day timeline lays out what to expect after you start. Bilingual support (English and Spanish) is available through the entire journey.

If you are ready for a personalized yes/no answer, start your Teledris GLP-1 evaluation. There is no cost or commitment to complete the intake — you only pay if you are approved and choose to continue.